Home > Urology > EAU 2019 > Bladder Cancer > Updated Interim Results of Phase 2 Trial of Pembrolizumab for High-risk NMIBC Unresponsive to BCG

Updated Interim Results of Phase 2 Trial of Pembrolizumab for High-risk NMIBC Unresponsive to BCG

Presented By
Prof. Ashish Kamat, MD Anderson Cancer Center, Houston, USA
Conference
EAU 2019
Trial
KEYNOTE-057, KEYNOTE-676

Updated results of KEYNOTE-057 among patients with non-muscle invasive bladder cancer (NMIBC) suggest that systemic immunotherapy with pembrolizumab (200 mg every 3 weeks) has encouraging activity in patients with high-risk, BCG-unresponsive CIS with or without papillary tumours.

Prof. Ashish Kamat (MD Anderson Cancer Center, Houston, USA) shared the interim update on immune checkpoint inhibitors which demonstrated efficacy in metastatic bladder cancer. The PD-1 inhibitor pembrolizumab was studied in BCG-unresponsive patients with CIS (+/- Ta or T1). Out of 103 patients, 31% had an impressive durable complete response, with no individuals progressing to MIBC or developing other metastases. These promising results have already led to the initiation of a phase 3 trial comparing the combination of systemic pembrolizumab plus intravesical BCG to re-introduction of BCG alone, currently open to enrolm...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on